These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 39046464)

  • 41. The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion.
    Sukhanov S; Higashi Y; Yoshida T; Mummidi S; Aroor AR; Jeffrey Russell J; Bender SB; DeMarco VG; Chandrasekar B
    Cell Signal; 2021 Jan; 77():109825. PubMed ID: 33160017
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression.
    Abdulrahman N; Ibrahim M; Joseph JM; Elkoubatry HM; Al-Shamasi AA; Rayan M; Gadeau AP; Ahmed R; Eldassouki H; Hasan A; Mraiche F
    Mol Cell Biochem; 2022 Jun; 477(6):1865-1872. PubMed ID: 35334035
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species.
    Li X; Römer G; Kerindongo RP; Hermanides J; Albrecht M; Hollmann MW; Zuurbier CJ; Preckel B; Weber NC
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34205045
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors.
    Scisciola L; Taktaz F; Fontanella RA; Pesapane A; Surina ; Cataldo V; Ghosh P; Franzese M; Puocci A; Paolisso P; Rafaniello C; Marfella R; Rizzo MR; Barbato E; Vanderheyden M; Barbieri M
    Cardiovasc Diabetol; 2023 Feb; 22(1):24. PubMed ID: 36732760
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway.
    Ni XY; Feng XJ; Wang ZH; Zhang Y; Little PJ; Cao Y; Xu SW; Tang LQ; Weng JP
    Acta Pharmacol Sin; 2024 Aug; 45(8):1604-1617. PubMed ID: 38589689
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
    Gangadharan Komala M; Gross S; Mudaliar H; Huang C; Pegg K; Mather A; Shen S; Pollock CA; Panchapakesan U
    PLoS One; 2014; 9(11):e108994. PubMed ID: 25369239
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of Secretome from Fat Tissues on Ion Currents of Cardiomyocyte Modulated by Sodium-Glucose Transporter 2 Inhibitor.
    Jhuo SJ; Liu IH; Tsai WC; Chou TW; Lin YH; Wu BN; Lee KT; Lai WT
    Molecules; 2020 Aug; 25(16):. PubMed ID: 32784369
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
    Li C; Zhang J; Xue M; Li X; Han F; Liu X; Xu L; Lu Y; Cheng Y; Li T; Yu X; Sun B; Chen L
    Cardiovasc Diabetol; 2019 Feb; 18(1):15. PubMed ID: 30710997
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SGLT2 inhibition leads to a restoration of hepatic and circulating metabolites involved in the folate cycle and pyrimidine biosynthesis.
    Mendez Espinoza I; Choos END; Ecelbarger CM; Shepard BD
    Am J Physiol Gastrointest Liver Physiol; 2024 Aug; 327(2):G235-G253. PubMed ID: 38915277
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: what is the evidence?
    Wichaiyo S; Saengklub N
    Heart Fail Rev; 2022 Nov; 27(6):1973-1990. PubMed ID: 35179683
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
    Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
    Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats.
    Durak A; Olgar Y; Degirmenci S; Akkus E; Tuncay E; Turan B
    Cardiovasc Diabetol; 2018 Nov; 17(1):144. PubMed ID: 30447687
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis.
    Jiang K; Xu Y; Wang D; Chen F; Tu Z; Qian J; Xu S; Xu Y; Hwa J; Li J; Shang H; Xiang Y
    Protein Cell; 2022 May; 13(5):336-359. PubMed ID: 33417139
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
    Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC
    Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Beneficial Effect of the SGLT2 Inhibitor Empagliflozin on Glucose Homeostasis and Cardiovascular Parameters in the Cohen Rosenthal Diabetic Hypertensive (CRDH) Rat.
    Younis F; Leor J; Abassi Z; Landa N; Rath L; Hollander K; Naftali-Shani N; Rosenthal T
    J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):358-371. PubMed ID: 29627992
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy.
    Yerra VG; Batchu SN; Kabir G; Advani SL; Liu Y; Siddiqi FS; Connelly KA; Advani A
    Cardiovasc Drugs Ther; 2022 Aug; 36(4):619-632. PubMed ID: 33886003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes.
    Ng KM; Lau YM; Dhandhania V; Cai ZJ; Lee YK; Lai WH; Tse HF; Siu CW
    Sci Rep; 2018 Oct; 8(1):14872. PubMed ID: 30291295
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of Empagliflozin on Vascular and Skeletal Mineralization in Hyperlipidemic Mice.
    Kalanski S; Pradhan S; Hon A; Xia Y; Safvati N; Rivera JC; Lu M; Demer LL; Tintut Y
    Vascul Pharmacol; 2024 Jun; 155():107376. PubMed ID: 38692418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.